EUCTR2011-002571-42-DE进行中（未招募）不适用
Phase IIa, multi-center, randomized, double-blind, vehicle-controlled study for assessment of clinical skin condition and effects on barrier impairment of a topical formulation containing tarenflurbil on lesional skin in subjects with mild to moderate atopic eczema
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •male or female subjects, 18 years or older;
- •manifest atopic dermatitis diagnosed according to Hanifin and Rajka (3);
- •two comparable lesional areas of 30 - 40 cm2 with a distance of at least 5 cm (difference in modified local SCORAD not greater than 2), clinical condition of atopic eczema mild to moderate; clinical condition of atopic eczema mild to moderate defined by a modified local SCORAD of at least 4 with
- •? erythema = 1
- •? lichenification = 1
- •? dryness = 1
- •TEWL in the lesional areas at least 12 g/m²h, TEWL value differences = 30 % are allowed between both lesional areas (related to the higher TEWL value);
- •the physical examination of the skin must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical trial;
- •female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner;
- •written informed consent obtained
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •acne, suntan, eczema other than atopic eczema, hyper- or hypopigmentation or tattoos in the treatment areas;
- •dark-skinned persons whose skin color prevents ready assessment of skin reactions;
- •evidence of drug or alcohol abuse;
- •pregnancy or nursing;
- •UV-therapy within 6 weeks before first treatment;
- •symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks before and during the trial;
- •participation in the treatment phase of another clinical trial within the last four weeks prior to the first administration of investigational drug in this clinical trial;
- •known allergic reactions to components of the investigational product/s;
- •treatment with systemic or locally acting medications which might counter or influence the trial aim within four weeks before the baseline visit and during the trial, e.g. antihistamines or glucocorticosteroids (exception: asthma may be found in patients with atopic dermatitis, therefore inhalation with corticosteroids in patients with asthma accompanying atopic dermatitis will be allowed);
- •in the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical trial, e.g. due to probable noncompliance or inability to understand the trial and give adequately informed consent;
- •close affiliation with the investigator (e.g. a close relative) or persons working at the study sites or subject is an employee of sponsor;
- •subject is institutionalized because of legal or regulatory order
研究者
相似试验
进行中（未招募）
不适用
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.EUCTR2004-004022-27-ESF.Hoffmann - La Roche Ltd160
进行中（未招募）
不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis.Fázis II, multicentrikus, randomizált, kettos vak, egyénenként placebóval kontrollált klinikai vizsgálat, különbözo koncentrációjú topikus P144 hatékonyságának és biztonságosságának megállapítása szisztémás sclerosis-ban szenvedo páciensek bor fibrózisának kezelésében.SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSISMedDRA version: 9.1Level: LLTClassification code 10039710Term: SclerodermaEUCTR2007-002015-38-HUISDI98
进行中（未招募）
不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis. - NDSkin Fibrosis in patients with systemic sclerosisMedDRA version: 12.0Level: LLTClassification code 10039710Term: SclerodermaEUCTR2007-002015-38-ITISDIN S.A.98
暂停
2 期
Clinical trial, phase II, to evaluate rhEGF efficacy and safety at a dose of 25 or 75 micrograms intralesionally in patients with diabetic foot ulcer (Wagner grade 1 or 2).Patients with diabetic foot ulcer (Wagner grade 1 or 2).Foot UlcerLeg UlcerSkin UlcerDiabetic AngiopathiesVascular DiseasesDiabetes ComplicationsDiabetic NeuropathiesEndocrine System DiseasesCardiovascular DiseasesDiabetic FootDiabetes MellitusRPCEC00000048Center for Genetic Engineering and Biotechnology (CIGB), Havana.35
进行中（未招募）
不适用
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioEUCTR2010-024616-33-SETROPHOS SA